Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression
2005 StandoutNobel
Structure and Function of Bone Marrow Hemopoiesis: Mechanisms of Response to Ionizing Radiation Exposure
2002
Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia
1998
In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors
2002
Total body irradiation regimens for marrow grafting
1990 StandoutNobel
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction
2001
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effect
1988
Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.
1998
Nutrition and physical activity guidelines for cancer survivors
2012 Standout
Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide
2008 Standout
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
A Review of the Research Literature on Evidence-Based Healthcare Design
2008 Standout
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
2002 Standout
Chronic graft-versus-host disease
2003 Standout
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
2005 Standout
Obesity and autologous stem cell transplantation in acute myeloid leukemia
2001
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
2004
A simple controlled‐rate freezing method without a rate‐controlled programmed freezer provides optimal conditions for both large‐scale and small‐scale cryopreservation of umbilical cord blood cells
2003 StandoutNobel
Graft-versus-host disease
2009 Standout
Monitoring of Epstein‐Barr virus load after hematopoietic stem cell transplantation for early intervention in post‐transplant lymphoproliferative disease
2008
Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation
2004
Framework PEACE: An organizational model for examining physical exercise across the cancer experience
2001
The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information
1990
Immunological reconstitution after hematopoietic cell transplantation – its relation to the contents of the graft
2008
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Presentation of Epstein-Barr virus latency antigens to CD8+, interferon-γ-secreting, T lymphocytes
1999 StandoutNobel
Haemopoiesis of transplanted patients with autologous marrows assessed by long‐term marrow culture
1994
Epstein–Barr Virus Infection
2000 Standout
Peripheral T- cell lymphomas: diagnosis and management
2003
Bone Marrow Transplantation
1993
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]
1995 Standout
American College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors
2010 Standout
Acute and chronic graft-versus-host disease in man
1986
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
2012 Standout
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
2003
Graft-versus-leukemia reactions after bone marrow transplantation
1990 Standout
Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers
1998
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease
1988
Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity
2000
Immune Interventions in Disease
1987
Cardiotoxicity of Cancer Therapy
2005
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
2005 Standout
Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers
1998
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
2002
Novel therapeutics for the treatment of graft-versus-host disease
2002
Clonogenic hemopoietic precursors in bone marrow transplantation
1987
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Risks of Developing Epstein-Barr Virus–Related Lymphoproliferative Disorders After T-Cell–Depleted Marrow Transplants
1998
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Works of T Schmeiser being referenced
Antimicrobial prophylaxis in neutropenic patients after bone marrow transplantation
1988
Fatal B-cell lymphoproliferative syndrome in allogeneic marrow graft recipients
1991
Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant.
1994
T‐cell depletion versus methotrexate as GvHD‐prophylaxis in allogeneic bone marrow transplantation for leukaemia
1988
Infectious complications after allogeneic bone marrow transplantation with and without T-cell depletion of donor marrow
1989
Extramedullary haemopoiesis after bone marrow transplantation
1985
Hemopoietic reconstitution after bone marrow transplantation.
1986
Ex vivo T‐cell depletion with the monoclonal antibody Campath‐1 plus human complement effectively prevents acute graft‐versus‐host disease in allogeneic bone marrow transplantation
1986
CYCLOSPORINE AS AN ALTERNATIVE TO CYCLOPHOSPHAMIDE IN THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
1986
EVIDENCE FOR THE INVOLVEMENT OF HOST-DERIVED OKT8-POSITIVE T CELLS IN THE REJECTION OF T-DEPLETED, HLA-IDENTICAL BONE MARROW GRAFTS
1987